Kevin McKernan

Anyone who can listen to this and disagree with it flat out does not understand how money works and why society is crumbling Saif is 1,000% right here

Before you start lecturing people about evidence, you might want to get the basic facts straight. Knouse completed her PhD in 2017 and her MD in 2018. She was an independent Whitehead Fellow, not a graduate student working in Sabatini’s laboratory when their relationship began. Yes, Sabatini had professional influence and served as a mentor. She actually requested him. Nobody is disputing that. But having a mentorship relationship, violating an institutional policy, and committing the acts subsequently alleged against him are three entirely different matters. Now, you asked why his lawsuit against Whitehead was dismissed. The Massachusetts Appeals Court upheld the dismissal of certain claims against Whitehead and Ruth Lehmann because their communications were protected by CONDITIONAL PRIVILEGE and the pleadings were insufficient to establish abuse of that privilege. It did NOT determine that Knouse’s allegations were true. It did NOT establish that the Hinckley Allen investigation was impartial. And it did NOT judicially validate Whitehead’s entire handling of the matter. In fact, the Appeals Court reversed Whitehead and Lehmann’s partial victory under the anti-SLAPP statute. Since those proceedings, additional communications have emerged raising questions about whether Lehmann contemplated removing Sabatini months before the investigation began. And thirteen jurors subsequently found Knouse liable for defamation and tortious interference, awarding Sabatini $6 MILLION. Sabatini’s attorneys reportedly intend to challenge the earlier institutional dismissals using additional evidence. I’ve addressed your arguments in Sections 4, 14–19, 30, 34, 39, and 40 of my published analysis. You might try reading them before confusing an institutional policy violation with proof that every allegation, investigative conclusion, and subsequent institutional action was legitimate. And the political insults are irrelevant. This is a question of evidence, law, and institutional accountability, not whether someone belongs to your preferred political tribe. And there’s another development you apparently missed. Sabatini’s attorneys spent YEARS fighting to obtain complete, unredacted communications. Knouse reportedly resisted producing her text messages for more than two years, and additional communications involving other individuals became the subject of further discovery disputes. Those communications are particularly consequential because some raise questions about what Whitehead leadership knew and whether Sabatini’s removal was being contemplated BEFORE the formal investigation began. More importantly, on November 4, 2026, Sabatini’s attorneys reportedly filed an appeal challenging the summary judgment entered in favor of Whitehead and Ruth Lehmann, as well as rulings denying access to additional investigative materials. So your suggestion that the dismissal somehow vindicated Whitehead is doubly misleading. The earlier rulings did not establish the investigation’s legitimacy, and the institutional litigation is now being challenged with a substantially expanded evidentiary record. The question is what that evidence establishes about Whitehead’s conduct, not whether Sabatini had a relationship that implicated institutional policy. I’ve addressed the distinction in Sections 15, 16, 28, 39, and 40. A dismissal based on conditional privilege is not a judicial declaration that the underlying accusations were true. And an institutional policy violation does not excuse knowingly false allegations or a compromised investigation. xitter.twitterapi.xyz/bruce_kris56597/status…

This week's podcast episode is my full @DohaDebates on the nature of money with two MMT economists, @jasonhickel and @ptcherneva. This was a good one you don't want to miss!

Your mitochondria can trigger the same inflammatory alarms your immune system uses to fight bacteria. That's because mitochondria are bacteria, or at least they were 1.5 billion years ago. A Nature Reviews Immunology paper maps the molecular mechanisms of how mitochondria control inflammation, the safeguards that normally prevent false alarms, and what happens when those systems fail. The core problem: mitochondria are ancient bacteria that your cells absorbed roughly 1.5 billion years ago. They still carry bacterial signatures. Your immune system evolved to recognize bacterial molecules as threats. When mitochondria get damaged and leak their contents, your immune system can't distinguish between a broken mitochondrion and an actual infection. Mitochondria contain multiple damage-associated molecular patterns, or DAMPs. These are molecules that trigger immune responses when detected outside their normal location: • Mitochondrial DNA (mtDNA): Unmethylated, circular DNA that resembles bacterial genomes • Cardiolipin: A phospholipid normally confined to the inner mitochondrial membrane • N-formyl peptides: Proteins with bacterial-style chemical signatures • ATP and other metabolites: Energy molecules that signal danger when released These molecules activate pattern recognition receptors, the sensors your immune system uses to detect threats. The most studied pathway involves mitochondrial DNA activating a detection system called cGAS-STING. Here's how it works: When mitochondria become damaged, their outer membrane develops holes. Think of it like a breach in a container. The mitochondrial DNA, which normally stays sealed inside, leaks out into the cytosol, the liquid interior of your cell. An enzyme called cGAS patrols the cytosol looking for DNA that shouldn't be there. When it finds mitochondrial DNA floating around, it produces a signaling molecule called cGAMP. This molecule activates another protein called STING, which sits on the endoplasmic reticulum, a membrane network inside cells. STING activation triggers the production of interferons, immune signaling proteins your body normally makes to fight viral infections. Your cell responds to leaked mitochondrial DNA the same way it responds to a virus. A second pathway involves cardiolipin, a fat molecule that normally stays on the inner membrane of mitochondria. When cardiolipin appears on the outer surface or leaks into the cytosol, it activates the NLRP3 inflammasome. This is a multi-protein assembly that acts like an alarm system. Once activated, it produces inflammatory molecules called cytokines, specifically IL-1β, which trigger inflammation throughout surrounding tissue. Your cells have multiple safeguards to prevent mitochondria from triggering these inflammatory pathways: Apoptosis suppresses inflammation. Apoptosis is programmed cell death, a controlled self-destruction process. When a cell commits to dying, it activates enzymes called caspases. These enzymes act like molecular scissors, rapidly cutting up mitochondrial DNA and other inflammatory molecules before they can activate immune sensors. Two key studies demonstrated that strong caspase activation prevents the cGAS-STING pathway from turning on during cell death. Mitophagy removes damaged mitochondria. Mitophagy is selective autophagy, meaning cellular recycling that targets only mitochondria. When mitochondria lose their electrical charge, called membrane potential, or accumulate too much damage, they get tagged with molecular markers. These tags signal cellular machinery to engulf the damaged mitochondrion inside a double-membrane structure called an autophagosome. The autophagosome fuses with a lysosome, which contains digestive enzymes that break down the damaged mitochondrion completely. This happens before its contents can leak out and trigger inflammation. Chromatin packaging inhibits cGAS. Your nuclear DNA is wrapped around proteins called histones and packaged into a structure called chromatin. This packaging prevents cGAS from detecting it. Mitochondrial DNA lacks this protective packaging, which makes it a much stronger activator of cGAS when it reaches the cytosol. This difference explains why leaked mitochondrial DNA triggers inflammation while nuclear DNA, even when exposed during normal cell division, generally does not. The pathological consequences emerge when these safeguards fail or get overwhelmed. Insufficient mitophagy allows damaged mitochondria to accumulate. Their contents gradually leak into the cytosol, triggering chronic low-grade inflammation. This process contributes to age-related inflammatory diseases, neurodegenerative disorders, and metabolic dysfunction. Defective apoptosis prevents proper DAMP degradation. Cells that can't complete programmed death release intact mitochondrial components that activate stronger inflammatory responses. This mechanism appears in some autoimmune conditions where defective clearance of dying cells drives chronic inflammation. Excessive mitochondrial stress overwhelms quality control. When mitochondrial damage happens faster than mitophagy can remove it, cells release mitochondrial DAMPs even with functioning safeguards. This occurs during ischemia-reperfusion injury, severe metabolic stress, and certain infections that specifically target mitochondria. The inflammation can become bidirectional. Inflammatory signals like TNF-α and interferons feed back to impair mitochondrial function, creating cycles where inflammation damages mitochondria and damaged mitochondria amplify inflammation. Several human diseases show clear links to dysregulated mitochondria-driven inflammation: Parkinson's disease involves mitochondrial dysfunction in dopaminergic neurons. Defective mitophagy allows damaged mitochondria to trigger inflammatory responses that accelerate neurodegeneration. Systemic lupus erythematosus shows elevated mtDNA in circulation and enhanced cGAS-STING activation. Defective clearance of dying cells releases mitochondrial contents that drive autoantibody production. COVID-19 severity correlates with cGAS-STING pathway activation. Viral infection triggers mitochondrial DNA release, and excessive type I interferon responses contribute to immunopathology. Cancer cells sometimes exploit insufficient mitochondria-driven inflammation. Tumors with defective inflammatory signaling evade immune surveillance, while therapeutic interventions that trigger controlled mitochondrial DAMP release can enhance anti-tumor immunity. The therapeutic implications point in two directions. For inflammatory diseases, blocking mitochondrial DAMP signaling could reduce pathological inflammation. cGAS-STING inhibitors are in development for autoimmune conditions. Enhancing mitophagy might prevent DAMP accumulation before inflammation starts. For cancer and infections, activating mitochondrial DAMP release could boost immunity. Some chemotherapy drugs work partly by triggering immunogenic cell death that releases mitochondrial DAMPs. Radiation therapy activates similar pathways. The central insight is that mitochondrial quality control and inflammation are mechanistically linked. The same cellular machinery that maintains energy metabolism also determines inflammatory state. When mitochondria function properly and damaged ones get cleared efficiently, inflammation remains appropriately regulated. When quality control fails, mitochondrial DAMPs drive pathological inflammatory responses. Your immune system treats broken mitochondria like invading bacteria because, evolutionarily, that's exactly what they once were. The molecular signatures persist. What determines health versus disease is how effectively your cells maintain mitochondrial integrity and clear damaged mitochondria before they trigger inappropriate immune activation.

EXCLUSIVE: MIT biologist caught demanding rough sex from professor then destroying his career with #MeToo lie breaks her silence 🔗 trib.al/kZX9a69

Remember when the cashier at CVS is trying to jab you with a shot, it's all about the money. Remember also that this cashier has no medical training and will be nowhere to be found when you have an adverse reaction.

Susie Wiles’s Son-In-Law Scrubs LinkedIn Posts Bragging About Securing Lucrative Farm Bill Carve-Outs dailycaller.com/2026/11/10/s…

Moderna's wicked new flu product (mFLUSIVA) just came out two months ago. Already there are 48 reports of injury in VAERS, representing a small fraction of the whole. They read very much like the early reports of the Covid poisons. Same signs. V-Safe entries clock the decline from fatigue to injection-site pain to headaches to rashes to GI issues to limb dysfunction and on and on, like a poisoning, ending in disability and sometimes death. You can see all the signs that this is happening right now with this new injection. Will no one at the FDA stop the madness before it is too late? openvaers.com/search-vaers?q…

Hey FDA - just a heads up your newly approved mRNA flu vaccine #mFLUSIVA has 48 reports in VAERS and it’s only been out 60 days? @FDADrugs @FDA @RobertKennedyJr @HHSResponse @Walgreens @cvspharmacy @Surgeon_General

Gene therapy's long-debated cancer risk materializes statnews.com/2026/11/09/biot…

Massie: "I hope Hegseth addresses the 8 articles of impeachment, and doesn‘t get up and misquote the Bible in Quentin Tarantino fashion and do some pull-ups and call everybody fat and gay. I may have just given you half his speech, I don't know."

In 2008, a network evening news show did something unthinkable today: it followed the money behind the "independent" experts who defend vaccine safety on TV. What it found about the most quoted one, the man who said babies could theoretically handle 10,000 vaccines at once, was stunning. 🧵

Sum Ting Wong with this headline

A 6 per 100,000 risk of eye conditions, including blindness, from the use of GLP-1 has lead the #FDA to require amending the prescribing instructions. FDA Slaps New Safety Warning on GLP-1 Drugs medpagetoday.com/ophthalmolo…

You might not be interested in geopolitics, but geopolitics is interested in you.